Karyopharm Therapeutics | KPTI - Ebitda


Karyopharm Therapeutics reported $-26.2M in EBITDA for its fiscal quarter ending in September of 2024.





Ebitda Change Date
AbbVie USD 6.91B 3.22B Jun/2026
Abbott USD 2.43B 844M Mar/2026
Amgen USD 5.8B 1.25B Sep/2026
AstraZeneca USD 7.46B 2.3B Sep/2026
BioCryst Pharmaceuticals USD 51.7M 30.14M Sep/2025
Bristol-Myers Squibb USD 3.48B 1.6B Sep/2026
Eli Lilly USD 9.46B 3.54B Sep/2026
GlaxoSmithKline GBP 3.51B 734M Jun/2026
Incyte USD 778.57M 410.6M Jun/2026
J&J USD 8.99B 721M Jun/2026
Karyopharm Therapeutics USD -26.2M 1.83M Sep/2024
MacroGenics USD -64.54M 34.34M Jun/2026
Merck USD 1.42B 2.97B Jun/2026
Nektar Therapeutics USD -38.9M 7.09M Mar/2026
Novartis USD 8.62B 2.14B Sep/2026
Novartis USD 5.36B 45M Sep/2026
Pfizer USD 6.36B 350M Sep/2026
Regeneron Pharmaceuticals USD 1.66B 695.2M Jun/2026
Roche Holding CHF 13.43B 744M Jun/2026
Takeda JPY 369.75B 5.29B Sep/2026
Tectonic Therapeutic USD -21.18M 365K Dec/2025
TG Therapeutics USD 26.9M 1.21M Jun/2026
Ultragenyx Pharmaceutical USD -61M 94M Jun/2026
Xencor USD 25.1M 59.73M Sep/2026